Targeting plasma cells in autoimmune diseases
- PMID: 15173204
- PMCID: PMC2211780
- DOI: 10.1084/jem.20040719
Targeting plasma cells in autoimmune diseases
Abstract
Antibodies specific for self-antigens mediate life-threatening pathology in several autoimmune diseases. Clearly the ability to target the plasma cells (PCs) producing the autoantibodies would be of great clinical benefit. Current immunosuppressive therapies are based on the premise that autoreactive PCs are short-lived and replenished from ongoing immune responses. However, recent results question this assumption and suggest that optimizing the treatment of severe autoimmune conditions will require a significant investment in elucidating the details of PC biology.
Figures
References
-
- Drenkard, C., A.R. Villa, C. Garcia-Padilla, M.E. Perez-Vazquez, and D. Alarcon-Segovia. 1996. Remission of systematic lupus erythematosus. Medicine (Baltimore). 75:88–98. - PubMed
-
- Looney, R.J., J. Anolik, and I. Sanz. 2004. B cells as therapeutic targets for rheumatic diseases. Curr. Opin. Rheumatol. 16:180–185. - PubMed
-
- Zinkernagel, R.M. 1996. Immunology taught by viruses. Science. 271:173–178. - PubMed
-
- Manz, R.A., A. Thiel, and A. Radbruch. 1997. Lifetime of plasma cells in the bone marrow. Nature. 388:133–134. - PubMed
-
- Slifka, M.K., R. Antia, J.K. Whitmire, and R. Ahmed. 1998. Humoral immunity due to long-lived plasma cells. Immunity. 8:363–372. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
